Roche Licenses Memory’s Lead CNS Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss firm exercises option on nicotinic alpha-7 receptor agonist, gives Memory needed cash infusion.
You may also be interested in...
Roche Cash Infusion Saves Partnered Memory Program, Allows Expanded Phase II Study
Memory halves its workforce to find funds for the cognitive impairment associated with schizophrenia program.
Roche Cash Infusion Saves Partnered Memory Program, Allows Expanded Phase II Study
Memory halves its workforce to find funds for the cognitive impairment associated with schizophrenia program.
Memory Revises Amgen Deal, Increases Focus On Clinical Candidates
New Jersey biotech will de-emphasize new drug discovery and reduce R&D workforce.